Clinical Trial Update: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Juventas Cell Therapy is conducting a Phase 2 trial of CNCT19 cell injection for relapsed or refractory acute lymphoblastic leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CNCT19 cell injection

Snippet

Sponsor: Juventas Cell Therapy Ltd. | Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING